EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Clinical implications of fracture severity risk with pioglitazone: a systematic review and meta-analysis of clinical randomized trials

Hala F Azhari, Jesse Dawson

Frontiers in Pharmacology · 06.03.2025 · 16

DOI: 10.3389/fphar.2025.1357309 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 06.03.2025. Verfasst von Hala F Azhari und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine and Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Pioglitazone, a thiazolidinedione, effectively reduces stroke and cardiovascular events in individuals with type 2 diabetes, insulin resistance, and/or stroke. However, its potential to increase fracture risk, particularly among women and those with pre-existing skeletal conditions, has not yet been completely understood. This meta-analysis aims to clarify fracture risk associated with pioglitazone, thereby focusing on individuals with a history of stroke.

Methods

A systematic review was performed for clinical trials conducted up to March 2024, focusing on trials comparing pioglitazone to placebo or other antihyperglycemic drugs that reported fracture outcomes.

Results

From 860 trials identified, 78 satisfied the inclusion criteria: 34 with a high risk of bias, 8 with unclear risk, and 36 with low risk. The meta-analysis revealed an association between pioglitazone and a significant increase in fracture risk (risk ratio [RR] 1.21; 95% CI 1.01–1.45; P = 0.04), including non-serious (RR 1.25; 95% CI 1.03–1.51; P = 0.02) and serious fractures (RR 1.48; 95% CI 1.10–1.98; P = 0.01). Notably, the risk was exacerbated for low-energy fractures, particularly resulting from falls (RR 1.49; 95% CI 1.20–1.87; P = 0.0004), in insulin resistance individuals (RR 0.87; 95% CI 0.43–1.76; P = 0.69), and stroke survivors (RR 1.41; 95% CI 1.09–1.83; P = 0.008). Fractures were most frequently observed in lower extremities (RR 1.85; 95% CI 1.33–2.56; P = 0.0002), with women at a greater risk (RR 1.56; 95% CI 1.20–2.02; P = 0.0008). When compared with other antihyperglycemic drugs, no significant difference in fracture risk was noted (RR 1.08; 95% CI 0.73–1.59; P = 0.70), except rosiglitazone, which showed higher fracture risk (RR 1.42; 95% CI 1.23–1.64; P < 0.00001). Fracture risk was significant in the fixed-effect model but not in the random-effects model.

Discussion

Though pioglitazone offers several cardiovascular benefits, its association with increased fracture risk, especially among women and non-diabetic individuals post-stroke, warrants careful consideration. Individualized treatment interventions balancing cardiovascular and skeletal outcomes are essential, and further research is needed to optimize therapeutic strategies in this population. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42016038242 , identifier CRD42016038242.

Schlagwörter

Stichwörter der Autor:innen

antihyperglycemicbone fracturepioglitazonerandomized clinical trialsrosiglitazonethiazolidinediones

Autor:innen und Institutionen

  • College of Medicine and Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
  • School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom.

Zitieren

APA

Azhari, H. F., & Dawson, J. (2025). Clinical implications of fracture severity risk with pioglitazone: a systematic review and meta-analysis of clinical randomized trials. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1357309

Vancouver

Azhari HF, Dawson J. Clinical implications of fracture severity risk with pioglitazone: a systematic review and meta-analysis of clinical randomized trials. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1357309

BibTeX
@article{Azhari2025,
  author = {Azhari, Hala F and Dawson, Jesse},
  title = {Clinical implications of fracture severity risk with pioglitazone: a systematic review and meta-analysis of clinical randomized trials},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1357309}
}
Kostenlos starten →